Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 5, 2014, Pages 313-322

  Li, Ping ^a   Chen, Quan ^a   Wang, Ya Di ^a   Ha, Min Wen ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMPUTER PROGRAM; DATA BASE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; META ANALYSIS; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; COLORECTAL NEOPLASMS; GENETICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC;

EID: 84899893187     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0494     Document Type: Article

References (43)

1. Akoglu B, Milovic V, Caspary WF, et al. (2004) Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate. Eur J Nutr 43:93-99
2. Arnesen E, Refsum H, Bonaa KH, et al. (1995) Serum total homocysteine and coronary heart disease. Int J Epidemiol 24:704-709
3. Banna GL, Collova E, Gebbia V, et al. (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36: 595-605
4. Botto LD, Yang Q (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151:862-877
5. Braun MS, Richman SD, Thompson L, et al. (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27:5519-5528
6. Budai B, Komlosi V, Adleff V, et al. (2012) Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI + bevacizumab. Pharmacogenet Genomics 22:69-72
7. Castillo-Fernandez O, Santibanez M, Bauza A, et al. (2010) Methylenetetrahydrofolate reductase polymorphism (677 C> T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res 41:430-435
8. Chen S, Yueh MF, Bigo C, et al. (2013) Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A 110:19143-19148
9. Choi SW, Mason JB (2002) Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 132:2413S-2418S
10. Cortejoso L, Lopez-Fernandez LA (2012) Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics 13:1173-1191
11. Cui LH, Shin MH, Kweon SS, et al. (2010) Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population. BMC Cancer 10:236
12. Curtin K, Bigler J, Slattery ML, et al. (2004) MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 13:285-292
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
14. Forges T, Chery C, Audonnet S, et al. (2010) Life-threatening methylenetetrahydrofolate reductase (MTHFR) deficiency with extremely early onset: characterization of two novel mutations in compound heterozygous patients. Mol Genet Metab 100:143-148
15. Glimelius B, Garmo H, Berglund A, et al. (2011) Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11:61-71
16. Gonen N, Assaraf YG (2012) Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 15:183-210
17. Kato I, Dnistrian AM, Schwartz M, et al. (1999) Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer 79:1917-1922
18. Kawakami K, Ruszkiewicz A, Bennett G, et al. (2003) The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 9:5860-5865
19. LaBonte MJ, Manegold PC, Wilson PM, et al. (2009) The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 125:2957-2969
20. Li R, Wang R, Li Y, et al. (2013) Association study on MTHFR polymorphisms and meningioma in northern China. Gene 516:291-293
21. Liew SC, Das-Gupta E, Wong SF, et al. (2012) Association of methylentetraydrofolate reductase (MTHFR) 677 C> T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study. Nutr J 11:1
22. Marcuello E, Altes A, Menoyo A, et al. (2006) Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57:835-840
23. Massacesi C, Terrazzino S, Marcucci F, et al. (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106:1007-1016
24. Ott K, Rachakonda PS, Panzram B, et al. (2011) DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol 18:2688-2698
25. Peters JL, Sutton AJ, Jones DR, et al. (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676-680
26. Ruzzo A, Graziano F, Loupakis F, et al. (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8:278-288
27. Sameer AS, Shah ZA, Nissar S, et al. (2011) Risk of colorectal cancer associated with the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the Kashmiri population. Genet Mol Res 10:1200-1210
28. Shulman K, Cohen I, Barnett-Griness O, et al. (2011) Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117:3156-3162
29. Sohda S, Arinami T, Hamada H, et al. (1997) Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 34:525-526
30. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605
31. Stankova J, Lawrance AK, Rozen R (2008) Methylenetetrahydrofolate reductase (MTHFR): a novel target for cancer therapy. Curr Pharm Des 14:1143-1150
32. Stocco G, Crews KR, Evans WE (2010) Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyltransferase status. Expert Opin Drug Saf 9:23-37
33. Swami U, Goel S, Mani S (2013) Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets 14:777-797
34. Thomas F, Motsinger-Reif AA, Hoskins JM, et al. (2011) Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 105:1654-1662
35. Toffoli G, Cecchin E (2004) Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate-and fluoropyrimidine-based chemotherapy. J Chemother 16 Suppl 4:31-35
36. Ueland PM, Hustad S, Schneede J, et al. (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195-201
37. van Huis-Tanja LH, Gelderblom H, Punt CJ, et al. (2013) MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. Pharmacogenet Genomics 23:208-218
38. Wallace BD, Wang H, Lane KT, et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831-835
39. Walther A, Johnstone E, Swanton C, et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489-499
40. Weisberg I, Tran P, Christensen B, et al. (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172
41. Yang L, Liu L, Wang J, et al. (2011) Polymorphisms in folaterelated genes: impact on risk of adult acute lymphoblastic leukemia rather than pediatric in Han Chinese. Leuk Lymphoma 52:1770-1776
42. Zarate R, Rodriguez J, Bandres E, et al. (2010) Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 102:987-994
43. Zintzaras E, Ioannidis JP (2005) HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 21:3672-3673.